Backed by extensive expertise in technology and healthcare investments, the fund manager has successfully executed over 30 deals across North America and Europe. Their strategic focus on early to growth-stage companies showcases a data-driven approach that emphasizes operational value creation. Noteworthy exits in the biotech sector underline their ability to identify high-potential opportunities. This investment style combines thematic insights with a hands-on operational perspective, ensuring robust portfolio performance.